# Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

**Publication ID:** GDA05162982  
**Publication Date:** May 31, 2016  
**Pages:** 93  
**Publisher:** GlobalData  
**Countries:** Global [1]  

$2,500.00

## Publication License Type *

- **SINGLE USER LICENSE (PDF), $2,500.00**
- **SITE LICENSE (PDF), $5,000.00**
- **GLOBAL LICENSE (PDF), $7,500.00**

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Clinical Trials [2]
Pharma & Healthcare [3]

Description:

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2016" provides an overview of Wilms' Tumor (Nephroblastoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Wilms' Tumor (Nephroblastoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with
reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents:

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials 17
List of Figures

Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 15
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 18
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27

Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Wilms' Tumor (Nephroblastoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Wilms' Tumor (Nephroblastoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19
Wilms' Tumor (Nephroblastoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Wilms' Tumor (Nephroblastoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Wilms' Tumor (Nephroblastoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
GlobalData Methodology 91

Companies Mentioned:

Children's Cancer and Leukaemia Group
Children's Healthcare of Atlanta Inc.
GlaxoSmithKline Plc
ImmunoGen, Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Chemo Espana, S.A.
Celtic Pharmaceutical Holdings L.P.
Cambridge Laboratories Limited
AbbVie Inc.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/globaldata/wilms-tumor-nephroblastoma-global-clinical-trials-review-h1-2016

Links